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Higher prevalence of physical comorbidity and premature mortality in persons with 
schizophrenia (PwS) results primarily from heightened cardiovascular and metabolic risks. 
The literature suggests that insulin resistance precedes the development of obesity, smoking, 
and use of antipsychotic medications, although these likely play a compounding role later 
in the course of the disorder. It is thus important to discover the clinical characteristics of 
PwS with high insulin resistance, as these individuals may represent an etiopathologically 
distinct subgroup with a distinct course and treatment needs. We conducted a cross-
sectional study and compared insulin resistance between 145 PwS and 140 nonpsychiatric 
comparison (NC) participants, similar in age, sex, and race distribution. In addition, we 
examined correlates of insulin resistance in PwS. As expected, PwS had higher levels of 
insulin resistance [Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)] and 
body mass index (BMI) compared to the NC participants. HOMA-IR in the PwS was most 
associated with negative symptoms, BMI, and non-White race/ethnicity. The mechanistic 
relationships between insulin resistance and negative symptoms in schizophrenia patients 
warrant further investigation, and future studies should examine outcomes of PwS with 
this cluster of physical and mental symptoms and determine how management of insulin 
resistance might improve health of these individuals.
Keywords: body mass index, cognitive function, depression, hemoglobin A1c, psychosis, antipsychotics
INTRODUCTION
The mortality gap between persons with schizophrenia (PwS) and the general population is 
driven, to a large extent, by cardiovascular disease-related deaths (1). Metabolic abnormalities and 
metabolic syndrome, which are highly prevalent among PwS, are strong independent predictors of 
cardiovascular-related mortality (2–4). Compared with healthy subjects, schizophrenia patients are 
more likely to have metabolic comorbidities, including obesity, impaired glucose homeostasis, and 
metabolic syndrome (5–8). Thus, understanding individual differences among PwS in the degree 
of metabolic dysfunction could help to identify subgroups who may have an accelerated course of 
aging and who may be good candidates for preventative measures to reduce morbidity and mortality.
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An important contributor to metabolic comorbidities 
is insulin resistance, which has been shown to precede the 
cumulative effects of antipsychotic medications, sedentary 
behaviors, unhealthy diet, and smoking (9–15). In a systematic 
review and meta-analysis by Pillinger et al. (16), impaired 
glucose homeostasis, including insulin resistance (Homeostatic 
Model Assessment of Insulin Resistance or HOMA-IR), was 
documented in antipsychotic-naive patients with first-episode 
schizophrenia. Several studies have shown elevated HOMA-IR 
levels in antipsychotic-naive patients with first-episode psychosis 
compared with age- and gender-matched controls with similar 
mean BMI values (17–21). Thus, altered insulin resistance 
may be part of a whole-body syndrome that manifests in the 
behavioral disorder of schizophrenia. Consistent with this view 
is growing evidence that schizophrenia phenotypes may share 
overlapping genetic loci with metabolic phenotypes (22, 23), 
and a Mendelian randomization study showing specifically that 
a genetic predisposition to higher fasting plasma insulin levels is 
causally linked to an increased risk of schizophrenia (24).
Little is known about the specific demographic and clinical 
features that characterize PwS who have elevated insulin resistance. 
Most studies to date have focused on correlates of more general 
metabolic abnormalities, such as metabolic syndrome and diabetes 
mellitus (DM). A study by Sicras-Mainar et al. (25) showed that, 
among 1,120 schizophrenia outpatients on antipsychotic treatment, 
the prevalence of metabolic syndrome was significantly higher in 
the patients with one or more negative symptoms (43.9%) than in 
those without any negative symptoms (34.9%). In a meta-analysis 
of 12 studies, Bora et al. (26) reported that metabolic syndrome and 
DM were both associated with more severe cognitive impairment. 
A focus on the correlates of insulin resistance, which seems 
to be among the earliest metabolic abnormalities and perhaps 
intrinsically linked to the pathophysiology of the disorder, may 
reveal a distinct subgroup of PwS who may have a unique course 
and could respond differently to treatments.
Our group has examined relationships between metabolic 
abnormalities and antipsychotic use. One study randomized 
middle-aged and older patients to one of four atypical 
antipsychotic medications and tracked metabolic and other 
adverse outcomes in middle-aged and older adults with 
schizophrenia and other psychiatric illnesses over 2 years (27). It 
showed that all the commonly used atypical antipsychotics carried 
similar high risk of metabolic pathology. The current study is a 
naturalistic evaluation of the association of other clinical factors 
(in addition to antipsychotic medication use) possibly related to 
metabolic dysfunction in a broader age group of PwS, using a 
multivariate approach. This type of information has considerable 
potential value for developing targeted interventions to reduce 
insulin resistance in PwS. This study presents findings from a 
large sample with extensive clinical phenotyping—allowing us 
to examine the relationships of insulin resistance with a number 
of key psychopathological, cognitive, and functioning measures, 
using multivariate methods to assess the relative contributions 
of different factors to metabolic abnormalities. PwS often have 
many risk factors for metabolic abnormalities: lifestyle habits, 
medications, and underlying biological mechanisms including 
inflammation and oxidative stress. Treatment and prevention of 
metabolic abnormalities in PwS can be particularly challenging 
due to these multiple risk factors (28–32). This study aims 
to better understand the factors most highly associated with 
metabolic dysfunction in this high-risk group.
In the present cross-sectional study, we aimed to compare 
insulin resistance between adults with chronic schizophrenia 
and nonpsychiatric comparison (NC) subjects, with similar age, 
sex, and race/ethnicity distribution. Furthermore, within the 
PwS we examined the relationships between insulin resistance 
and psychopathology, cognition, and everyday functioning. 
We performed targeted statistical analyses using the least 
absolute shrinkage and selection operator (LASSO) method 
to see what group of factors were most associated with insulin 
resistance in PwS. These findings will help us better understand 
what patient characteristics and clinical factors would predict 
response to interventions to prevent or treat diabetes in PwS. 
This knowledge would help develop preventive and therapeutic 
interventions to reduce insulin resistance in schizophrenia and 
thereby reduce some of the excess morbidity and mortality 
that characterizes this serious mental and physical illness. We 
hypothesized that PwS would have worse insulin resistance 
compared to NCs. We also hypothesized that HOMA-IR would 
be related to worse psychopathology, cognitive performance, and 
everyday functioning within the schizophrenia group, even while 
controlling for BMI and other clinical covariates.
MATERIALS AND METHODS
Study Participants
We recruited 145 persons with chronic schizophrenia receiving 
outpatient psychiatric treatment and 140 NCs from the greater 
San Diego area, ranging in age from 26 to 65 years. Analyses on 
subsets of these data have been reported previously (33–37). The 
Human Research Protections Program at University of California 
San Diego approved the study protocol. All participants provided 
written informed consent prior to participation. The Structured 
Clinical Interview for the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition−Text Revision (DSM-IV-TR, 
SCID) was used to determine schizophrenia diagnosis (38). The 
Mini-International Neuropsychiatric Interview (MINI) (39) 
was used to screen NC participants who did not have major 
neuropsychiatric disorders. Exclusion criteria were as follows: 
1) other current DSM-IV-TR Axis I diagnoses; 2) alcohol or other 
substance use disorders (except nicotine or caffeine) within prior 
3 months; 3) diagnosis of dementia, intellectual disability disorders, 
or other major neurological disorders; and 4) any medical 
disability affecting the ability to complete study procedures. 
Trained research staff interviewed the study participants, reviewed 
available medical records, and administered standardized physical 
and psychological assessments in person.
Sociodemographic Variables
Demographic features included in the present analysis included 
age, sex, race/ethnicity, education, and cigarette smoking (Table 1).
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Psychopathology
Dose equivalents of antipsychotics were based on the defined 
daily dose (DDD; the assumed average maintenance dose per day 
for a drug used for its main indication in adults) presented by 
the World Health Organization Collaborating Centre for Drug 
Statistics and Methodology (40). Duration of illness was assessed 
for all PwS.
Positive symptoms were measured by using the Scale for 
the Assessment of Positive Symptoms (SAPS) (41). Negative 
symptoms were measured by using the Scale for the Assessment 
of Negative Symptoms (SANS) (41, 42).
Depressive symptoms were assessed with the nine-item 
Patient Health Questionnaire (PHQ-9, total score range 0–27) 
(43). Perceived stress was measured with the 10-item Perceived 
Stress Scale (PSS-10, total score range 0–40); and higher scores 
indicated more severe perceived stress (44).
Cognitive Performance, Quality of Life, 
and Everyday Functioning
All cognitive testing was done in face-to-face interviews. Global 
cognitive functioning was evaluated with the Telephone Interview 
for Cognitive Status−Modified (TICS-M, 12-item, total score 
range 0−50), performed during an in-person assessment using 
the phone script (45–48). TICS-M has been shown to have high 
sensitivity (82.4%) and specificity (87.0%) for detecting amnestic 
mild cognitive impairment in community-dwelling older adults 
(46). Executive functioning was assessed with selected subsets of 
the Delis-Kaplan Executive Function System (D-KEFS) (49, 50), 
including Trail Making Letter-Number Sequencing, Color Word 
Inhibition (Switching), and Letter Fluency (FAS total). We used 
standardized z-scores from these D-KEFS subtests in order to 
create a composite score of executive functioning, as previously 
described by Palmer et al. (51). Mental health-related quality of 
life was measured with the 36-item Short Form Health Survey, 
Mental Component Summary (SF-36 MCS) (52, 53). UCSD 
Performance-Based Assessment-Brief (UPSA-B) is a test of 
everyday functioning across a variety of community-based tasks 
(54, 55). In all these measures, higher scores indicated better 
functioning.
Metabolic Measures
The body mass index [BMI = bodyweight (kg)/height (m)2] was 
also assessed based on standard measurements.
Fasting venous blood was used for biochemical assays 
including plasma glucose (mmol/L) and plasma insulin 
(mU/L). Both assays were conducted in the Altman Clinical 
and Translational Research Institute (ACTRI) laboratory at 
University of California San Diego. The level of insulin resistance 
was estimated with the homeostatic model assessment of insulin 
resistance {HOMA-IR = [fasting plasma insulin (mU/L) × fasting 
plasma glucose (mmol/L)]/22.5, giving normal HOMA-IR of 1} 
(56, 57). HOMA-IR, a steady-state basal test, was validated 
as a surrogate marker of insulin resistance with reference to 
standard stimulated-state tests of insulin resistance such as the 
hyperinsulinemic-euglycemic clamp (57).
Statistical Analysis
All variables were assessed for violation of distribution 
assumptions (skew and kurtosis) and, if appropriate, were log-
transformed. The schizophrenia and NC groups were compared 
using independent samples t-test (continuous variables) or 
Spearman’s rho (categorical variables).
In the PwS and NC groups, pairwise associations of insulin 
resistance to clinical, medical, and psychological (continuous) 
variables were assessed with Spearman’s rho. The null of common 
FIGURE 1 | Correlation of negative symptoms with insulin resistance in persons with schizophrenia, stratified by BMI status.
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Spearman’s correlation between the schizophrenia and NC 
groups was tested by comparing two independent Spearman’s 
correlations.
We performed multiple regression analyses, aided by LASSO 
variable selection, to identify the best multivariable model 
for HOMA-IR. In the multiple regression analysis, regression 
coefficients were made commensurate by standardizing each 
variable. Independent variables were ranked by the order in 
which they entered the LASSO regression. LASSO overcomes 
various limitations of classic variable selection procedures such 
as multicollinearity to provide reliable selection of independent 
variables (58). Independent variables selected by LASSO were 
entered into the linear model for further trimming using 
backward elimination, as univariate analysis may also miss 
significant predictors, and such models may be biased (59). 
Multicollinearity of the independent variables was assessed using 
variance inflation factor (VIF) (60).
For all analyses, unadjusted two-tailed p-values were 
considered significant at p < 0.05. Significance was defined 
as Type I error alpha = 0.05 (two-tailed) for all analyses, and 
false discovery rate (FDR) was used to account for multiple 
comparisons to ensure overall Type 1 error at alpha = 0.05. 
The statistical analyses were conducted using the IBM SPSS 
Version 25 (IBM Corp., Armonk, New York, USA) and R.
RESULTS
Group Comparisons
Characteristics of the schizophrenia and NC groups and group 
differences in the measured variables are presented in Table 1. 
The two groups were similar in the distribution of age, sex, 
and race/ethnicity, although PwS had fewer years of education 
and longer duration of cigarette smoking (p < 0.001, both). As 
expected, the PwS endorsed worse depressive symptoms and 
perceived stress and had worse cognitive functioning, quality of 
life, and everyday functioning (p < 0.0005, all).
The schizophrenia group had higher levels of insulin resistance 
(HOMA-IR, t258 = −4.66, p < 0.001); in addition, BMI was higher 
(t277 = −5.38, p < 0.001). In terms of diabetes treatment, 6% of NCs 
and 23% of PwS reported current use of diabetes medications. 
HOMA-IR levels were significantly higher among the PwS on 
diabetes medications, compared to those not taking medications 
[5.67 (SD = 6.0) vs. 3.12 (SD = 4.6), t47.0 = −2.75, p = 0.009].
TABLE 1 | Comparison of study participants with and without schizophrenia.
Nonpsychiatric comparison group Schizophrenia group
N Mean SD N Mean SD t or χ2 df p Cohen’s d
Sociodemographic variables
Age (years) 140 48.7 11.2 145 48.3 10.1 0.27 283 0.79 0.03
Sex (% female) 140 54 145 46 1.85 1 0.17
Race/ethnicity 140 145 4.93 2 0.09
 Non-Hispanic White (%) 58 45
 Hispanic (%) 24 30
 Other (%) 18 25
Education (years) 140 14.5 2.3 145 12.4 2.3 8.16 283 <0.001 0.97
Cigarette use (packs per day) 140 0.02 0.09 145 0.38 0.50 −8.49 283 <0.001 −1.01
Psychopathology
Antipsychotic daily dose1 145 1.85 1.56
Duration of illness (years) 142 25.0 11.1
Positive symptoms (SAPS) 145 6.52 4.20
Negative symptoms (SANS) 145 7.21 4.35
Depression (PHQ-9) 130 1.95 2.81 138 7.80 6.59 −9.37 266 <0.001 −1.16
Perceived stress (PSS) 130 10.9 6.04 141 18.7 6.20 −10.5 269 <0.001 −1.28
Cognitive performance, quality of life, and everyday functioning 
Global functioning (TICS-M) 138 37.4 4.22 141 31.0 6.02 10.2 277 <0.001 1.23
Executive functioning (D-KEFS) 140 0.39 0.61 145 −0.57 0.75 11.8 283 <0.001 1.40
Quality of life (SF-36) 131 54.7 5.83 141 42.8 11.26 10.8 270 <0.001 1.32
Everyday functioning (UPSA-B) 140 84.2 9.9 139 67.7 18.1 9.50 277 <0.001 1.14
Metabolic measures
Body mass index 139 27.6 6.64 140 32.2 7.35 −5.38 277 <0.001 −0.64
Insulin resistance (HOMA-IR) 126 1.74 1.57 134 3.73 5.07 −4.66 258 <0.001 −0.58
For all measures (except the depression and perceived stress), lower scores suggest worse functioning. D-KEFS, Delis-Kaplan Executive Function System (49, 50); 
HOMA-IR, Homeostatic Model Assessment of Insulin Resistance (56, 57); PHQ-9, Patient Health Questionnaire-9; measure of depression (43); PSS, Perceived Stress Scale; 
measure of perceived stress (44); SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; SF-36, Medical Outcomes 
Survey—Short Form 36; measure of mental and physical functioning (61); TICS-M, Telephone Interview for Cognitive Status—Modified (45, 46); UPSA-B, UCSD Performance-
Based Assessment-Brief (54, 55).
1Antipsychotic medication daily dosages were converted to WHO average daily doses based on published standards (40).
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Pairwise Correlates of Insulin Resistance
Among the PwS, worse insulin resistance (HOMA-IR) was 
associated with younger age, higher BMI, worse negative 
symptoms, worse global cognitive performance, worse quality 
of life, and worse everyday functioning (Table 2, Figure 1). 
Antipsychotic dose, duration of illness, and positive symptoms 
were not associated with HOMA-IR within the PwS.
Regression Analyses
The best-fit regression model for HOMA-IR had the following 
factors emerge as significantly associated with higher HOMA-IR: 
worse negative symptoms, higher BMI, and non-White race/
ethnicity (Table 3). Collinearity was minimal with VIF < 1.2 for 
all variables.
DISCUSSION
Consistent with our hypothesis, we found that insulin resistance 
was worse in PwS compared to the NC group. We also found 
that HOMA-IR was related to several variables when considered 
individually, but the best-fit linear model found non-White 
race/ethnicity, higher BMI, and worse negative symptoms to 
be associated with higher HOMA-IR levels in PwS. Positive 
symptoms, antipsychotic dosage, and duration of illness were not 
associated with HOMA-IR levels in the PwS. Several measures 
that were significantly associated individually with HOMA-IR, 
such as age, quality of life, cognitive performance, and everyday 
functioning, did not emerge in the multivariate models.
Similar to other published studies (5–8), the sample of 
PwS studied in the present study had worse psychopathology, 
cognitive performance, and everyday functioning, as well as 
higher HOMA-IR and BMI compared with NCs of similar 
age, sex, and race/ethnicity distribution (26, 62–67). Thus, the 
findings presented here are likely generalizable to other groups of 
adults with chronic schizophrenia.
We found an association of insulin resistance (HOMA-IR) with 
negative symptoms (SANS) in a model that also included BMI 
and race/ethnicity as significant predictors. Previous observational 
studies reported associations of metabolic comorbidities such 
as fasting plasma glucose levels (68), DM (26), and metabolic 
syndrome (25, 26) with specific psychological symptoms in chronic 
schizophrenia patients. In antipsychotic-naive patients with first-
episode schizophrenia, Chen et al. (19) found that patients with 
impaired glucose tolerance (assessed with the 75-g oral glucose 
tolerance test, n = 43) had more severe negative symptoms [assessed 
with the Positive and Negative Syndrome Scale (PANSS)] than those 
without (n = 129) after controlling for age and age of illness onset. 
In contrast, in another study of antipsychotic-naive patients with 
TABLE 3 | Best-fit general linear models of insulin resistance within persons with 
schizophrenia (N = 145).
 Variable B SE FDR-adjusted p
Race/ethnicity (Hispanic) 0.18 0.09 0.05
Race/ethnicity (other) 0.19 0.09 0.05
Body mass index 0.02 0.005 <0.001
Negative symptoms (SANS) 0.02 0.008 0.01
SANS, Scale for the Assessment of Negative Symptoms.
TABLE 2 | Spearman’s correlations of insulin resistance (HOMA-IR) in participants with and without schizophrenia.
Nonpsychiatric comparison group Schizophrenia group Test for equal 
correlations
N rho p N rho p z p
Sociodemographic variables
Age (years) 126 0.10 0.29 134 −0.18 0.04 2.25 0.02
Education (years) 126 −0.16 0.08 134 −0.04 0.62 −0.97 0.33
Cigarette use (packs per day) 126 0.12 0.19 134 −0.16 0.06 2.25 0.02
Psychopathology
Antipsychotic daily dose1 134 0.07 0.42
Duration of illness (years) 131 −0.06 0.49
Body mass index 126 0.55 <0.001 132 0.53 <0.001 0.22 0.83
Positive symptoms (SAPS) 134 0.04 0.69
Negative symptoms (SANS) 134 0.23 0.007
Depression (PHQ-9) 117 0.15 0.10 128 0.17 0.06 −0.16 0.87
Perceived stress (PSS) 116 0.18 0.05 131 0.15 0.09 0.24 0.81
Cognitive performance, quality of life, and everyday functioning
Global functioning (TICS-M) 125 −0.35 <0.001 130 −0.28 0.02 −0.61 0.54
Executive functioning (D-KEFS) 126 −0.29 0.001 134 −0.06 0.46 −1.90 0.06
Quality of life (SF-36) 117 −0.15 0.11 131 −0.23 0.01 0.64 0.52
Everyday functioning (UPSA-B) 126 −0.13 0.16 130 −0.21 0.02 0.65 0.52
For all measures (except the depression and perceived stress), lower scores suggest worse functioning. D-KEFS, Delis-Kaplan Executive Function System (49, 50); 
HOMA-IR, Homeostatic Model Assessment of Insulin Resistance (56, 57); PHQ-9, Patient Health Questionnaire-9; measure of depression (43); PSS, Perceived Stress Scale; 
measure of perceived stress (44); SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; SF-36, Medical Outcomes 
Survey—Short Form 36; measure of mental and physical functioning (61); TICS-M, Telephone Interview for Cognitive Status—Modified (45, 46); UPSA-B, UCSD Performance-
Based Assessment-Brief (54, 55).
1Antipsychotic medication daily dosages were converted to WHO average daily doses based on published standards (40).
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first-episode schizophrenia, Steiner et al. (20) found no significant 
correlation between the level of insulin resistance (HOMA-IR) and 
the severity of negative symptoms (PANSS). However, in this study of 
acute schizophrenia (20), the level of insulin resistance (HOMA-IR) 
was relatively low (given normal HOMA-IR of 1) and the sample 
size was small {median [interquartile range (IQR)] HOMA-IR  = 
0.72 [0.38, 2.28], n = 24}, as compared with those parameters in our 
present study of chronic schizophrenia (median [IQR] HOMA-IR = 
2.08 [1.21, 4.66], n = 134). It is conceivable that the relationship 
between insulin resistance (HOMA-IR) and negative symptoms of 
schizophrenia is dependent on the chronicity and severity of illness.
PwS with negative symptoms have been shown to have more 
severe overall psychopathology, worse cognition, poorer every 
day functioning, and lower physical activity (69, 70). Negative 
symptoms may impede help-seeking behaviors and healthcare 
utilization (71). Thus, PwS with higher levels of negative 
symptoms may have worse lifestyle behaviors resulting in poorer 
physical health including greater insulin resistance.
The exact biological processes underlying the relationship 
of negative symptoms with insulin resistance are unclear. 
However, dysregulated hypothalamic–pituitary–adrenal (HPA) axis 
responses and dopamine D2 receptor activity are involved in both 
psychopathology of schizophrenia and insulin resistance (72, 
73). Unexpectedly, PwS with significant negative symptoms were 
reported to have higher HDL cholesterol levels, which may reflect 
altered lipid metabolism at the neuronal and systemic levels 
(74), as well as different patterns of cerebral metabolic activity 
(75). Adjunctive medications that improve metabolic side effects 
of antipsychotic medications (e.g., topiramate and pioglitazone) 
have been shown to also improve negative symptoms (76, 77), 
possibly through the AMPA/KA receptor antagonism and 
inhibition of NF-κB expression, respectively. Similarly, exercise 
has been shown to improve negative symptoms, possibly through 
increasing serum brain-derived neurotrophic factor and insulin-
like growth factor-1 levels (78). Thus, there is a biological basis 
for our findings. The relationships between insulin resistance 
and negative symptoms warrant further investigation, especially 
when targeting interventions for metabolic problems and 
psychopathology for persons with chronic schizophrenia.
The present study had some limitations. Data on exogenous 
insulin therapy in our study participants were not available, 
although we did assess current use of diabetes medications. 
There are multiple possible contributors to metabolic pathology 
in schizophrenia. These include lifestyle factors such as physical 
activity, diet, and sedentary behavior, atypical antipsychotics, 
and biology of schizophrenia itself (37, 79, 80). In this study, we 
did not assess lifestyle factors in a systematic way and, therefore 
cannot comment on their role in the association between 
negative symptoms and insulin resistance. We found higher 
HOMA-IR levels among the PwS on diabetes medications, 
compared to PwS not taking medications. The use of HOMA-IR 
to assess insulin resistance in individuals specifically on insulin 
therapy warrants further investigation (57, 81). Furthermore, 
this is an examination of cross-sectional data to examine insulin 
resistance, which is highly dependent on longitudinal factors—
duration of illness, age, exposure to antipsychotic medications, 
and other issues. Thus, causality cannot be inferred, though we 
did include certain time-related factors (duration of illness, daily 
dose of antipsychotic medications) into our multivariate analyses. 
Finally, the schizophrenia group consisted of outpatients with a 
chronic and relatively stable course of illness. The results of the 
present study may not be generalized to antipsychotic-naive 
patients with first-episode or acute schizophrenia or hospitalized 
severely ill patients.
In conclusion, we found that PwS who have higher insulin 
resistance also have worse negative symptoms as well as higher BMI. 
Thus, efforts to prevent metabolic comorbidities and subsequent 
cardiovascular disease and death among chronic patients should 
focus on PwS with this clinical profile. Our cross-sectional study 
was not able to discern the temporal relationship among these 
factors. It is possible, for example, that heightened insulin resistance 
could be the consequence of unhealthy lifestyle secondary to 
sedentary behaviors associated with greater negative symptoms in 
the prodrome or throughout the course of illness (8, 68, 82–85). 
However, it is also possible, given evidence that insulin resistance 
exists early in the course of the illness and is linked to genetic risk 
for the disorder, that glucose dysregulation is a part and parcel of 
the schizophrenia syndrome, at least for some patients. If so, it may 
be that a subsyndrome exists in those with high negative symptoms, 
high BMI, and high insulin resistance.
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